Assuming patients is required, the following results were found.

  • More Access Needed for Medication-Assisted Treatment, Experts Say

    WASHINGTON -- States need to do more to get patients with opioid addiction on to medication-assisted treatment (MAT), experts said Monday at an event sponsored by the American Medical Association (AMA). "MAT [is] the gold standard," said Joel Ario, JD,...

    https://mschristian.org/index.php/articles/2-uncategorised/8550-more-access-needed-for-medication-assisted-treatment-experts-say
  • PTAC OKs Model to Boost Stroke Care at Rural Hospitals

    WASHINGTON -- A telemedicine-based payment model to improve care for patients experiencing stroke and other cerebral emergencies in rural, underserved communities won support from the Physician-Focused Payment Model Technical Advisory Committee (PTAC)....

    https://mschristian.org/index.php/articles/2-uncategorised/8655-ptac-oks-model-to-boost-stroke-care-at-rural-hospitals
  • Cannabidiol Cuts Seizures in Another Rare Epilepsy

    BALTIMORE -- Adjunctive cannabidiol, or CBD, (Epidiolex) met its primary endpoint of reducing seizures in patients with tuberous sclerosis complex (TSC), a rare and severe form of childhood-onset epilepsy, a phase III pivotal trial showed here. Seizure...

    https://mschristian.org/index.php/articles/2-uncategorised/9497-cannabidiol-cuts-seizures-in-another-rare-epilepsy
  • #ECTRIMS2019 - Mayzent's Benefits for MS Patients a 'Key Question,' Says EXPAND's Principal Investigator - Multiple Sclerosis News Today

    Data from the EXPAND study (NCT01665144) was one of the key pieces of evidence for Mayzent’s approval. Involving 1,651 patients with SPMS (both active and non-active), the study showed that taking 2 mg tablets of Mayzent once per day reduced the risk of...

    https://mschristian.org/index.php/blog/ectrims2019-mayzent-s-benefits-for-ms-patients-a-key-question-says-expand-s-principal-investigator-multiple-sclerosis-news-today
  • New treatment shows promise to reverse celiac disease

    to induce immune tolerance to gluten in individuals with celiac disease. The findings may pave the way for treated celiac patients to eventually tolerate gluten in their diet. After treatment with the technology, the patients were able to eat gluten...

    https://mschristian.org/index.php/blog/new-treatment-shows-promise-to-reverse-celiac-disease
  • Stem cell transplant reverses disabling MS-like disease - Medical Xpress

    Credit: CC0 Public Domain A stem cell transplant reversed a debilitating neurological disease that causes half of the patients to go blind and lose the ability to walk five years after diagnosis. Most of the patients stayed better five years after the...

    https://mschristian.org/index.php/blog/stem-cell-transplant-reverses-disabling-ms-like-disease-medical-xpress
  • Siponimod Delays Time to Wheelchair in Secondary Progressive MS - Neurology Times

    the EXPAND study population has suggested that siponimod (Mayzent, Novartis) may have an additional long-term benefit for patients with secondary progressive multiple sclerosis (MS) beyond the study’s core findings. The oral selective...

    https://mschristian.org/index.php/blog/siponimod-delays-time-to-wheelchair-in-secondary-progressive-ms-neurology-times
  • Cannabis-based drug in combination with other anti-spasticity

    Oral spray containing two compounds derived from the cannabis plant reduced spasticity compared with placebo in patients already taking anti-spasticity drugs. Chemical compounds derived from the cannabis sativa plant given as an add-on treatment may...

    https://mschristian.org/index.php/blog/cannabis-based-drug-in-combination-with-other-anti-spasticity
  • Common treatment for multiple sclerosis may prolong life

    Institute have found that a widely prescribed drug for multiple sclerosis (MS) is associated with longer survival for patients. The study, published today in the journal Brain, found that people with MS who took a beta interferon drug had a 32 per cent...

    https://mschristian.org/index.php/blog/common-treatment-for-multiple-sclerosis-may-prolong-life
  • EMA committee recommends caution in use of tofacitinib owing to increased risk of blood clots - The Pharmaceutical Journal

    tofacitinib (Xeljanz; Pfizer) could increase the risk of blood clots in the lungs and should be used with caution in all patients already at high risk. Tofacitinib is indicated for moderate-to-severe active rheumatoid arthritis (RA) in patients who have...

    https://mschristian.org/index.php/blog/ema-committee-recommends-caution-in-use-of-tofacitinib-owing-to-increased-risk-of-blood-clots-the-pharmaceutical-journal
  • Rare Shrew-Borne Illness Tied to Fatal Encephalitis

    confirmed via deep sequencing, antigen detection, and reactive antibodies in serum and cerebrospinal fluid. Of these 56 patients, 28 did not have a definite diagnosis, with nine dying from encephalitis and 15 surviving the disease. In seven ofnine of...

    https://mschristian.org/index.php/blog/rare-shrew-borne-illness-tied-to-fatal-encephalitis
  • Prescription digital therapeutics: reimagining disease treatment - STAT

    clinicians, and engineers working in tandem to leverage the power of software to treat disease. They are designed so patients can access treatment when and where they need it. Similar to traditional medicines, PDTs are prescribed by physicians and...

    https://mschristian.org/index.php/articles/2-uncategorised/9077-prescription-digital-therapeutics-reimagining-disease-treatment-stat
  • 7T MRI offers new insights into multiple sclerosis

    Investigators use powerful imaging technology to reveal that a potential MRI marker of brain inflammation is common among patients with early MS and may be a sign of gray matter injury BRIGHAM AND WOMEN'S HOSPITAL Boston, MA -- Increased immune system...

    https://mschristian.org/index.php/articles/2-uncategorised/9236-7t-mri-offers-new-insights-into-multiple-sclerosis
  • Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2 - Science

    potential for toxicity, which became apparent in initial studies in rodents (4) and subsequent clinical experience in patients (5, 6). Thus, the production of and response to type I IFNs must be tightly controlled (7). Transcriptional biomarker studies...

    https://mschristian.org/index.php/articles/2-uncategorised/9542-severe-type-i-interferonopathy-and-unrestrained-interferon-signaling-due-to-a-homozygous-germline-mutation-in-stat2-science
  • Rare Shrew-Borne Illness Tied to Fatal Encephalitis

    confirmed via deep sequencing, antigen detection, and reactive antibodies in serum and cerebrospinal fluid. Of these 56 patients, 28 did not have a definite diagnosis, with nine dying from encephalitis and 15 surviving the disease. In seven of nine of...

    https://mschristian.org/index.php/articles/2-uncategorised/9716-rare-shrew-borne-illness-tied-to-fatal-encephalitis
  • A robotic suit, called an exoskeleton, is part of a Cleveland Clinic study looking to help MS patients walk easier

    central nervous system, Kathy has seen her symptoms worsen over time, especially in recent years. Kathy is one of five MS patients at Cleveland Clinic’s Mellen Center for Multiple Sclerosis to participate in a research study assessing the effectiveness...

    https://mschristian.org/index.php/articles/2-uncategorised/9866-a-robotic-suit-called-an-exoskeleton-is-part-of-a-cleveland-clinic-study-looking-to-help-ms-patients-walk-easier
  • ADA 2020 Roundup: Simponi Preserves Beta Cells in Kids With T1D

    included the prevention of new-onset diabetes with dapagliflozin, safety of ertugliflozin for the heart in type 2 diabetes patients, and slashed rates of ketoacidosis with continuous glucose monitoring. The meeting also reported updates in diabetes care...

    https://mschristian.org/index.php/ada-2020-roundup-simponi-preserves-beta-cells-in-kids-with-t1d
  • Can Anti-TNF Drugs Reduce Alzheimer's Risk?

    diseases involving tumor necrosis factor (TNF) increased the risk of Alzheimer's disease, but that risk was reduced in patients who used anti-TNF biologics, an analysis of 56 million adults' electronic health records showed. While rheumatoid arthritis...

    https://mschristian.org/index.php/articles/2-uncategorised/8833-can-anti-tnf-drugs-reduce-alzheimer-s-risk
  • Muscle Relaxant Tied to Severe Confusion in CKD Patients

    WASHINGTON -- Patients with chronic kidney disease (CKD) prescribed baclofen (Lioresal) were at an increased risk of being hospitalized with delirium, disorientation, or other manifestations of encephalopathy, a Canadian researcher said here. Among...

    https://mschristian.org/index.php/articles/2-uncategorised/9234-muscle-relaxant-tied-to-severe-confusion-in-ckd-patients
  • Mindfulness training shows promise for people with MS

    New research suggests mindfulness training may help multiple sclerosis patients in two very different ways: regulating negative emotions and improving processing speed. People with MS who underwent the four-week mindfulness training not only improved...

    https://mschristian.org/index.php/articles/2-uncategorised/10850-mindfulness-training-shows-promise-for-people-with-ms

Results 61 - 80 of 484